{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=40",
    "query": {
      "intervention": "Control Capsules",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 2904,
    "total_pages": 291,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T00:47:34.893Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02346630",
      "title": "Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Levodopa / Carbidopa",
          "type": "DRUG"
        },
        {
          "name": "Armeo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Ross D. Zafonte, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-03",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2021-12-27",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02346630"
    },
    {
      "nct_id": "NCT00980330",
      "title": "A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "TMC435",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Peg-IFN-alfa-2a (P)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec Pharmaceuticals, Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 463,
      "start_date": "2009-10",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980330"
    },
    {
      "nct_id": "NCT04971109",
      "title": "Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "TPOXX",
          "type": "DRUG"
        },
        {
          "name": "TPOXX Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SIGA Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 467,
      "start_date": "2022-03-29",
      "completion_date": "2023-05-12",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 9,
      "location_summary": "Miami, Florida • Orlando, Florida • Omaha, Nebraska + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04971109"
    },
    {
      "nct_id": "NCT00267930",
      "title": "Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Vernakalant (oral)",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanz Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 221,
      "start_date": "2005-12",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2008-12-18",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 4,
      "location_summary": "Huntsville, Alabama • Walnut Creek, California • Hershey, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267930"
    },
    {
      "nct_id": "NCT06837298",
      "title": "The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Muscle Damage",
        "Muscle"
      ],
      "interventions": [
        {
          "name": "Placebo control capsules",
          "type": "OTHER"
        },
        {
          "name": "PeptiStrong® supplement capsules with same appearance as placebo capsules",
          "type": "OTHER"
        },
        {
          "name": "PeptiStrong® supplement capsules following muscle damaging exercise on Day 14",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "PepsiCo Global R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 76,
      "start_date": "2025-02-07",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 1,
      "location_summary": "Bradenton, Florida",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06837298"
    },
    {
      "nct_id": "NCT02469298",
      "title": "Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Virus Diseases"
      ],
      "interventions": [
        {
          "name": "GSK1325756 (Danirixin)",
          "type": "DRUG"
        },
        {
          "name": "Placebo To Match GSK1325756",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo To Match Oseltamivir Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 45,
      "start_date": "2015-06-01",
      "completion_date": "2016-04-25",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 5,
      "location_summary": "Palmetto Bay, Florida • Blackfoot, Idaho • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Blackfoot",
          "state": "Idaho"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02469298"
    },
    {
      "nct_id": "NCT02576639",
      "title": "Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CNP520",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "60 Years to 80 Years"
      },
      "enrollment_count": 124,
      "start_date": "2015-08-10",
      "completion_date": "2016-03-11",
      "has_results": true,
      "last_update_posted_date": "2017-08-11",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Long Beach, California • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576639"
    },
    {
      "nct_id": "NCT04697719",
      "title": "Body Weight, Aspirin Dose and Pro-resolving Mediators",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Body Weight"
      ],
      "interventions": [
        {
          "name": "Aspirin 81mg",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 325mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 108,
      "start_date": "2021-11-04",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04697719"
    },
    {
      "nct_id": "NCT01081964",
      "title": "Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Zabofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin 500mg",
          "type": "DRUG"
        },
        {
          "name": "Zabofloxacin 400mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IASO Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2010-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-05-07",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 13,
      "location_summary": "Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Toney",
          "state": "Alabama"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Eagle",
          "state": "Idaho"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081964"
    },
    {
      "nct_id": "NCT01545349",
      "title": "Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Lactobacillus rhamnosus GG ATCC 53103 (LGG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Live attenuated influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Patricia L. Hibberd",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "65 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-02",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-10-30T00:47:34.893Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545349"
    }
  ]
}